Bio-Rad and Gencurix Expand European Access to Precision Cancer Testing

Bio-Rad Laboratories has extended its partnership with Korean diagnostics company Gencurix through a new strategic agreement that will make Droplex digital PCR oncology testing kits more widely available across Europe.

The deal establishes Bio-Rad as the exclusive distributor of Gencurix’s CE-IVD marked Droplex assays, which run on Bio-Rad’s QXDx ddPCR systems. The kits enable highly sensitive mutation detection from formalin-fixed paraffin-embedded samples and liquid biopsies in several major cancers, including melanoma, colorectal cancer and non-small cell lung cancer.

The agreement builds on the companies’ existing collaboration and includes provisions for joint marketing as well as collaborative product development. It aims to accelerate access to advanced diagnostic tools that support precision medicine in oncology.

“We are proud to partner with Gencurix to expand our ddPCR offering and deliver CE-IVD marked ddPCR oncology diagnostics kits to laboratories across Europe,” said Steve Kulisch, Vice President Product Management, Digital Biology Group, Bio-Rad Laboratories.

“This partnership will provide clinical laboratories with access to highly sensitive and reliable molecular tools, supporting compliance while ensuring the highest standards of diagnostic accuracy. Most importantly, Gencurix’ Droplex testing kits, combined with our QXDx ddPCR platform, will enable physicians to make more informed treatment decisions based on biomarker testing, thereby contributing to improved patient outcomes.”

“This newly expanded strategic partnership with Bio-Rad represents a significant milestone for Gencurix, validating the clinical value of our Droplex technology,” said Sang Rae Cho, CEO of Gencurix. “Bio-Rad's extensive European distribution capabilities and deep expertise in digital PCR technology make them the ideal partner to bring our oncology testing solutions to a broader market. This partnership will accelerate access to our innovative diagnostic tools for oncology applications throughout Europe, supporting improved patient outcomes through precision medicine.”

As the demand for biomarker-driven treatment selection continues to grow, the expanded partnership positions both companies to play a larger role in delivering reliable molecular diagnostics to European oncology laboratories